学会速報レポート

ESMO Congress 2019

海外学会などで発表されたホットでタイムリーな演題を専門医が厳選。レポートとコメントを掲載します。

ESMO Congress 2019

2019年9月27日~10月1日にバルセロナで開催されたESMO Congress 2019 より消化器癌の注目演題のレポートを掲載しています。

ESMO Congress 2019 FLASH REPORT - 526PD -

TRIUMPH: Primary efficacy of a phase II trial of trastuzumab (T) and pertuzumab (P) in patients (pts) with metastatic colorectal cancer (mCRC) with HER2 (ERBB2) amplification (amp) in tumour tissue or circulating tumour DNA (ctDNA): A GOZILA sub-study

ESMO Congress 2019 FLASH REPORT - 525O -

ACHIEVE-2 trial: a randomized phase III trial investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with high-risk stage II colon cancer (CC)

ESMO Congress 2019 FLASH REPORT - 11740 -

Pembrolizumab in microsatellite instability high cancer: Updated analysis of the phase II KEYNOTE-164 and KEYNOTE-158 studies
L.A. Diaz, D. Le, M. Maio, et al.

ESMO Congress 2019 FLASH REPORT - Abstract LBA11 -

Nivolumab Versus Chemotherapy in Advanced Esophageal Squamous Cell Carcinoma : The ATTRACTION-3 study / Cho BC, et al

ESMO Congress 2019 FLASH REPORT - Abstract LBA33 -

Lefitolimod vs standard of care (SOC) for patients with metastatic colorectal cancer (mCRC) responding to first-line standard treatment: Results from the randomized phase III IMPALA trial. / Salazar R, et al.

ESMO Congress 2019 FLASH REPORT - LBA30_PR -

Analysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: Prognostic and predictive value for adjuvant treatment duration (ID 5478)

ESMO Congress 2019 FLASH REPORT - 4511 -

POLO: Health-related quality of life (HRQoL) of olaparib maintenance treatment versus placebo in patients with a germline BRCA mutation and metastatic pancreatic cancer

ESMO Congress 2019 FLASH REPORT - Abstract 2449 -

Conversion rate in locally advanced pancreatic cancer (LAPC) after nab-Paclitaxel/Gemcitabine-vs。FOLFIRINOX-based induction chemotherapy (NEOLAP_AIO-PAK-013 Trial). / V. Kunzmann, et al.

ESMO Congress 2019 FLASH REPORT - LBA38_PR -

CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line treatment in patients with advanced hepatocellular carcinoma (aHCC). / Thomas Yau, et al.

ESMO Congress 2019 FLASH REPORT - Abstract LBA90 -

Abstract LBA90
Primary analysis results of randomized controlled trial evaluating reactive topical corticosteroid strategies for the facial acneiform rash by EGFR inhibitors(EGFRIs) in patient(pts) with RAS wildtype(wt) metastatic colorectal cancer(mCRC) -FAEISS study-. / Yamazaki N, et al.

ESMO Congress 2019 FLASH REPORT - Abstract LBA43 -

Randomized phase 3 ANGEL study of rivoceranib (apatinib) + best supportive care (BSC) vs placebo + BSC in patients with advanced/metastatic gastric cancer who failed ≥2 prior chemotherapy regimens / Kang Y-K, et al.

ESMO Congress 2019 FLASH REPORT - LBA10_PR -

LBA10_PR
ClarlDHy: A global, phase III, randomized, double-blind study of ivosidenib (IVO) vs placebo in patinets with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation
G.K. Abou-Alfa, T. Macarulla, M. Javle, et al.

ESMO Congress 2019 FLASH REPORT - Abstract LBA39 -

Abstract LBA39 : Randomised efficacy and safety results for atezilizumab + bevacizumab in patients with hepatocellular carcinoa. / Michael S Lee, et al.

ESMO Congress 2019 FLASH REPORT - Abstract LBA40 -

Abstract FIGHT-202 : A phase 2 study of pemigatinib in patients with previously treated locally advanced or metastatic cholangiocarcinoma. / Vogel A, et al.